Bienvenue sur notre site
La Recherche
Nos Publications
Nos Partenaires
Venir chez nous
Bonne lecture
Nous contacter
quelques liens


Veuillez trouver ci-dessous la liste des principales publications des membres du laboratoire:

25. Gibaud, S., Attivi, D. (2012). Microemulsions for oral administration and their therapeutic applications. Expert Opin Drug Deliv., 9(8) , 937-951

24. Rodgers, J., Jones, A., Gibaud, S., Bradley, B., McCabe, C., Barrett, M. P., Gettinby G., Kennedy, P. G. E. (2011). Melarsoprol cyclodextrin inclusion complexes as promising oral candidates for the treatment of human african trypanosomiasis. PLoS Neglected Tropical Diseases, 5(9).

23. Attivi, D., & Gibaud, S. (2011). Role of mitotane in the management of adrenal cortex carcinoma. [Place du mitotane dans la prise en charge du carcinome corticosurré nalien] Actualites Pharmaceutiques Hospitalieres, 7(25), 39-41.

22. Gibaud, S., & Jaouen, G. (2010). Arsenic-based drugs: From fowler's solution to modern anticancer chemotherapy, 32, 1-20.

21. Ajana, I., Astier, A., & Gibaud, S. (2010). Speciation of arsenic in urine following intravenous administration of arsthinol in mice. European Journal of Drug Metabolism and Pharmacokinetics, 35(1-2), 59-65.

20. Attivi, D., Ajana, I., Astier, A., Demoré, B., & Gibaud, S. (2010). Development of microemulsion of mitotane for improvement of oral bioavailability. Drug Development and Industrial Pharmacy, 36(4), 421-427.

19. Ajana, I., Astier, A., & Gibaud, S. (2009). Arsthinol nanosuspensions: Pharmacokinetics and anti-leukaemic activity on NB4 promyelocytic leukaemia cells. Journal of Pharmacy and Pharmacology, 61(10), 1295-1301.

18. Gibaud, S. (2009). From recombinant erythropoietin to erythropoiesis-stimulating agents. [De l'érythropoïétine recombinante aux agents stimulant l'érythropoïèse] Actualites Pharmaceutiques Hospitalieres, (18), 23-26.

17. Ben Zirar S., Astier A., Muchow M., Gibaud S. Comparison of nanosuspensions and hydroxypropyl-ß-cyclodextrin complex of melarsoprol: pharmacokinetics and tissue distribution in mice. Eur.J. Pharm. Biopharm. Eur J Pharm Biopharm. 2008 Oct;70(2):649-56

16. Gibaud S, Astier A. Organoarsenicals derived from 2-phenyl-[1,3,2]dithiarsolan-4-yl)-methanol (AsIII) with antileukaemic properties: from trypanosomicides to anticancer drugs. Ann Pharm. Fr., 65(3), 162-168, 2007

15. Ben Zirar S, Gibaud S, Camut A, Astier A. Pharmacokinetics and tissue distribution of the antileukemic organoarsenicals arsthinol and melarsoprol in mice. J. Organometallic Chem., 692 (6 Spec Issue), 1348-1352, 2007

14. Brun H, Paul M., Gibaud S, Binhas M., Astier A. Formation and characterization of cyclodextrin inclusion complexes with Nefopam, Drug Dev. Ind. Pharm., Drug Dev. Ind. Pharm. 32, 1-12, 2006

13. S. Gibaud, A. Alfonsi, P. Muntzenhardt, I Fries, A. Astier. (2-Phenyl-[1,2,3]dithiarsolan-4-yl)methanol derivatives show in vitro antileukemic activity. J. Organometallic Chem., 2006;691(5): 1081-1084

12. S. Gibaud, S. Ben Zirar, P. Muntzenhardt, I. Fries, A. Astier. Melarsoprol-cyclodextrins inclusion complexes, Int. J. Pharm. 2005; 306: 107-121.

11. A. Astier, MJ Ferrer, S. Gibaud. Enhancement by 1-(2-chloroethyl)- 3-cyclohexyl- 1-nitrosourea (CCNU) of the cytotoxic properties of 1-ß-d-arabinofuranosylcytosine (Ara-C) on human promyelocytic leukemia cell line HL-60. Eur J Hosp Pharm Sci, 2005 ; 3 :31-36.

10. Gibaud S, Jabir Al Awwadi N, Ducki C, Astier A. Poly([epsilon]-caprolactone) and Eudragit(R) microparticles containing fludrocortisone acetate. International Journal of Pharmaceutics. 2004;269:491-508

9. Gibaud S, Bonneville A, Astier A. Preparation of 3,4-diaminopyridine microparticles by solvent-evaporation methods. Int J Pharm. 2002;242:197-201

8. Gibaud S, Gaia A, Astier A. Slow-release melarsoprol microparticles. Int J Pharm. 2002;243:161-166

7 . Gibaud S, Weingarten C, Andreux JP, Couvreur P. [Targeting bone marrow with the help of polyalkylcyanoacrylate nanoparticles]. Ann Pharm Fr. 1999;57:324-331

6. Gibaud S, Rousseau C, Weingarten C, Favier R, Douay L, Andreux JP, Couvreur P. Polyalkylcyanoacrylate nanoparticles as carriers for granulocyte-colony stimulating factor (G-CSF). J Control Release. 1998;52:131-139

5. Page-Clisson M-E, Gibaud S, Pinto-Alphandary H, Weingarten C, Couvreur P. Polyisobutylcyanoacrylate nanoparticles as drug carriers: influence of sulfur dioxide on the physico-chemical characteristics of ciprofloxacin- and doxorubicin-loaded nanoparticles. International Journal of Pharmaceutics. 1998;166:117-120.

4. Demoy M, Gibaud S, Andreux JP, Weingarten C, Gouritin B, Couvreur P. Splenic trapping of nanoparticles: complementary approaches for in situ studies. Pharm Res. 1997;14:463-468

3 . Gibaud S, Demoy M, Andreux JP, Weingarten C, Gouritin B, Couvreur P. Cells involved in the capture of nanoparticles in hematopoietic organs. J Pharm Sci. 1996;85:944-950

2. Gibaud S, Andreux JP, Weingarten C, Renard M, Couvreur P. Increased bone marrow toxicity of doxorubicin bound to nanoparticles. Eur J Cancer. 1994;30A:820-826

1. Decool A, Goury V, Tibi A, Gibaud S, Vincent F, Darbord JC. Detection of bacterial adenosine triphosphate through bioluminescence, applied to a rapid sterility test of injectable preparations. Analytica Chimica Acta. 1991;255:423-425

Gibaud, S., Attivi, D. (2012). Microemulsions for oral administration and their therapeutic applications. Expert Opin Drug Deliv., 9(8) , 937-951




[ Site internet : ]